
CLAIMS


1. A compound of formula (II),



(II)

wherein n is selected from 0.1 to 2.

2. The compound according to claim 1, wherein n is selected from 0.1, 0.5, 1, 1.5, and 2.
3. The compound according to claim 2, wherein n is 2.
4. A crystal form A of a compound of formula (II),



(II)

wherein n is selected from 1 to 2,


which is characterized by X-ray powder diffraction pattern with characteristic diffraction peaks at 2θ angles of 8.514±0.200°, 14.689±0.200°, and 18.122±0.200°.

5. The crystal form A according to claim 4, which is characterized by X-ray powder diffraction pattern with characteristic diffraction peaks at 2θ angles of 6.218±0.200°, 8.514±0.200°, 12.299±0.200°, 14.689±0.200°, 16.903±0.200°, 18.122±0.200°, 18.927±0.200°, and 25.580±0.200°.
6. The crystal form A according to claim 5, which is characterized by X-ray powder diffraction pattern with characteristic diffraction peaks at 2θ angles of 6.218±0.200°, 8.514±0.200°, 11.663±0.200°, 12.299±0.200°, 14.689±0.200°, 16.903±0.200°, 18.122±0.200°, 18.927±0.200°, 19.364±0.200°, 20.386±0.200°, 21.914±0.200°, and 25.580±0.200°.
7. The crystal form A according to claim 6, which is characterized by X-ray powder diffraction pattern with characteristic diffraction peaks at 2θ angles of 6.218°, 8.514°, 11.663°, 12.299°,

14.689°, 16.903°, 18.122°, 18.554°, 18.927°, 19.364°, 20.386°, 21.914°, 22.640°, 23.867°, 24.553°, 24.806°, 25.580°, 25.988°, 27.147°, 27.715°, 29.135°, and 31.799°.

8. The crystal form A according to claim 7, which has an XRPD pattern as shown in Figure 1.
9. The crystal form A according to any one of claims 4 to 8, which has a differential scanning calorimetry curve with a peak value of an endothermic peak at 115.37 ºC±3 ºC.
10. The crystal form A according to claim 9, which has a DSC curve as shown in Figure 2.
11. The crystal form A according to any one of claims 4 to 10, which has a thermogravimetric analysis curve with a weight loss of up to 5.379% at 150.0 ºC±3 ºC.
12. The crystal form A according to claim 11, which has a TGA curve as shown in Figure 3.
13. The crystal form A according to any one of claims 4 to 8, wherein n is 2.
14. A method of preparing the crystal form A of a compound of formula (II) according to any one of claims 4 to 13, including:

(a) adding a compound of formula (I) to ethanol, and stirring the mixture until clear;



(I)

(b) slowly adding water to the system while stirring, and adding seed crystals at 20 to 30 ºC;

(c) stirring at 20 to 30 ºC for 15 hours;

(d) slowly adding dropwise water into the reaction system at 20 to 30 ºC, and further stirring for 1 to 3 hours;

(e) filtering, and collecting a solid.

15. A medicament, comprising the compound according to any one of claims 1 to 3, or the crystal form A according to any one of claims 4 to 13, or the crystal form A of a compound of formula (II) prepared according to the method of claim 14.
16. Use of the compound according to any one of claims 1 to 3, or the crystal form A according to any one of claims 4 to 13, or the crystal form A of a compound of formula (II) prepared according to the method of claim 14, or the medicament according to claim 15 in the manufacture of a medicament for the treatment of solid tumors.
17. The use according to claim 16, wherein the solid tumors are selected from lung cancer and rectal cancer.